Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656981 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
NCT00656981 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 541 participants.
The verdict
NCT00656981, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
Study Summary
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles
Interventions
- DRUG Placebo
- DRUG YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656981
The ClinicalTrials.gov registry entry for NCT00656981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 541 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00656981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656981 about?
NCT00656981 is a clinical study titled "Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne". The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles
What is the current status of trial NCT00656981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2003-01. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00656981?
The interventions under investigation include: Placebo (DRUG), YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) (DRUG).
Who is sponsoring clinical trial NCT00656981?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.